- Trogenix’s breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancers
- Financing round led by IQ Capital with…
Trogenix announces £70 million / $95 million Series A
